CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK8-IN-12
CAS:<p>CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.</p>Fórmula:C21H20ClN3O2Pureza:99.46% - 99.83%Cor e Forma:SoildPeso molecular:381.86TMX-2138
CAS:<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Fórmula:C40H43BrFN9O11SCor e Forma:SolidPeso molecular:956.791FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Cor e Forma:LiquidLL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Fórmula:C37H43N5OCor e Forma:SolidPeso molecular:573.77Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidXY028-133
CAS:<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Fórmula:C53H67N11O7SPureza:97.11%Cor e Forma:SolidPeso molecular:1002.23CDK2-IN-19
<p>CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].</p>Fórmula:C20H21FN6O4SPureza:98%Cor e Forma:SolidPeso molecular:460.48CDK9-IN-27
<p>CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest.</p>Fórmula:C23H18ClN5O3Pureza:98%Cor e Forma:SolidPeso molecular:447.87PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Fórmula:C43H56N10O5Cor e Forma:SolidPeso molecular:792.97CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Fórmula:C32H34FN7O4Cor e Forma:SolidPeso molecular:599.655CP-07
<p>CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formation</p>Fórmula:C45H48N6O8Pureza:98%Cor e Forma:SolidPeso molecular:800.9CDK1-IN-2
CAS:<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Fórmula:C17H11ClN2OPureza:98.53%Cor e Forma:SoildPeso molecular:294.73Ribociclib hydrochloride
CAS:<p>Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Fórmula:C23H31ClN8OPureza:98%Cor e Forma:SolidPeso molecular:471NCT02
CAS:<p>NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.</p>Fórmula:C17H16N2O2SCor e Forma:SolidPeso molecular:312.39NU6102
CAS:<p>NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.</p>Fórmula:C18H22N6O3SPureza:99.76%Cor e Forma:SolidPeso molecular:402.47LDC4297
CAS:<p>LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.</p>Fórmula:C23H28N8OPureza:98.25%Cor e Forma:SolidPeso molecular:432.52(E/Z)-Zotiraciclib hydrochloride
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3.</p>Fórmula:C23H25ClN4OCor e Forma:SolidPeso molecular:408.93GP-82996
CAS:<p>GP-82996 (CINK4) inhibits CDK4/6; IC50s: 1.5 μM (CDK4/D1), 5.6 μM (CDK6/D1), 25 μM (Cdk5/p35); triggers U2OS cancer cell apoptosis.</p>Fórmula:C27H32N6OPureza:99.94%Cor e Forma:SolidPeso molecular:456.58CDK5-IN-3
CAS:<p>CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.</p>Fórmula:C22H26N4OPureza:98.21%Cor e Forma:SolidPeso molecular:362.47Palbociclib-d8
CAS:<p>Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.</p>Fórmula:C24H21D8N7O2Pureza:98%Cor e Forma:SolidPeso molecular:455.58
